Salicylic acid (2-hydroxybenzoic acid) is a lipophilic beta-hydroxy acid with a pKa of 2.97 and an experimental log P of approximately 2.26; the compound dissolves in water at a ratio of about 1 g in 460 mL at 25 °C, in ethanol at 1 g in 2.7 mL, and in diethyl ether at 1 g in 3 mL. These solubility characteristics determine the formulation strategies used in compounded dermatological preparations, because the non-ionized acid partitions into the stratum corneum more readily than the salicylate anion. At pH 2.0 the non-ionized fraction is approximately 90%; at pH 3.0 the non-ionized fraction falls to approximately 48%; and at pH 4.0 it drops below 10%. Keratolytic activity is therefore not solely a function of total salicylic acid concentration but also of the free acid concentration in the applied vehicle, the ionization state at the formulation pH, the release rate from the semisolid matrix, and the degree of stratum corneum hydration at the application site. Salicylic acid reduces intercorneocyte cohesion by disrupting corneodesmosomal adhesion and by lowering the local pH of the hydrated stratum corneum from the physiological range of 5.4–5.9 toward 3.0–4.0, a shift that alters the activity of pH-dependent enzymes involved in desmosomal degradation. This action is described as keratolytic when the result is detachment and shedding of superficial corneocytes, but the same compound can behave as a keratoplastic or comedolytic agent at concentrations below approximately 2% w/w. The distinction has practical consequences in compounding: a 0.5% w/w salicylic acid gel intended for acne is not interchangeable with a 6% w/w ointment intended for hyperkeratotic plaques, even though the active pharmaceutical ingredient is identical.

Concentration thresholds that separate keratoplastic, keratolytic, and destructive action

The United States Food and Drug Administration OTC monograph for acne drug products, 21 CFR 333.310, recognizes salicylic acid as an active ingredient at concentrations from 0.5% w/w to 2.0% w/w; the OTC wart remover monograph, 21 CFR 358.310, lists salicylic acid at 12% w/w to 40% w/w in a suitable vehicle such as collodion or a medicated plaster. Compounded nonsterile preparations fall outside these monographs when they are prepared under USP <795> for individual patients, but the concentration ranges remain clinically relevant because they define the expected biological response. At 0.5% w/w to 2.0% w/w, salicylic acid is generally keratoplastic and comedolytic; at 2.0% w/w to 10.0% w/w, the predominant action on hyperkeratotic skin is keratolytic; at 10.0% w/w to 30.0% w/w, the effect on plantar callus can become destructive to the stratum corneum; and at 12.0% w/w to 40.0% w/w, the wart remover monograph recognizes keratolytic activity sufficient to remove infected keratinized tissue. These boundaries are not sharp; the clinical response depends on the vehicle, the application site, the degree of hydration, occlusion, and the duration of contact. A compounded preparation containing 6% w/w salicylic acid in white petrolatum may produce only modest keratolysis on thick plantar skin because the lipophilic matrix retains the active and limits release, whereas the same concentration in a hydrophilic ointment or in a flexible collodion film produces more rapid desquamation.

Within anhydrous ointment bases, the release of salicylic acid follows a biphasic pattern controlled by the degree of particle dissolution in the ointment film at the skin interface. In white petrolatum, the active is largely suspended, and release is limited by dissolution into the thin ointment layer and by partitioning between the lipophilic base and the stratum corneum lipids. In polyethylene glycol ointment bases, salicylic acid is more readily dissolved because of the polar ether and hydroxyl character of the base, and the release rate from a compounded hydrophilic ointment can substantially exceed the release rate from white petrolatum when tested under identical conditions in a Franz diffusion cell. The addition of a volatile solvent such as ethanol to a salicylic acid gel shifts the release profile further: ethanol evaporates after application, transiently increasing the thermodynamic activity of the active in the residual film and driving penetration into the upper stratum corneum. In a hydroalcoholic gel, the ionization state is controlled by the buffer capacity of the gelling agent. Carbomer 980 requires neutralization with triethanolamine or sodium hydroxide to develop its yield stress, but triethanolamine raises the pH above the salicylic acid pKa and forms an amine salt that reduces the free acid fraction. Addition of salicylic acid in ethanol before neutralization can reduce the final yield stress by more than 30% compared with a gel of identical carbomer content that does not contain salicylic acid; hydroxyethylcellulose or a pre-neutralized carbomer dispersion is therefore preferred when the formulation pH must remain below 3.5 to preserve the non-ionized free acid fraction.

Why do flexible collodion vehicles amplify salicylic acid activity on plantar skin?

The amplification of salicylic acid activity in flexible collodion vehicles is not due to a change in the active moiety but to occlusion, solvent evaporation, and film-induced hydration. Flexible collodion typically contains pyroxylin in a volatile ether-ethanol solvent system with castor oil and camphor as plasticizers; after application, the solvent evaporates and deposits a nitrocellulose film that reduces transepidermal water loss. The resulting increase in plantar stratum corneum hydration can reach 40–60% after 24 h of continuous occlusion, and hydrated keratin is more susceptible to corneodesmolytic loosening by salicylic acid. The same vehicle also maintains the applied salicylic acid in a high-concentration reservoir at the skin surface, rather than allowing it to be rubbed off or diluted by perspiration. In the OTC wart remover monograph 21 CFR 358.310, salicylic acid concentrations of 12% w/w to 40% w/w are used in collodion or plaster vehicles because the occlusive film is necessary to achieve sufficient keratolysis on thick plantar skin. A compounded flexible collodion preparation containing 17% w/w salicylic acid and 10% w/w lactic acid is used in some dermatological practices for localized plantar warts; the addition of lactic acid lowers the formulation pH and further disrupts intercorneocyte cohesion, but the combination requires careful application to avoid erosion of the surrounding uninvolved skin. Published comparative release data for this specific compounded configuration are limited, but the separate contributions of occlusion, free acid concentration, and vehicle film formation are well established.

USP <795> beyond-use date categories, pH adjustment, and preservative requirements

Under USP <795>, a compounded nonsterile preparation must receive a beyond-use date assigned from the compendial category unless a stability-specific study supports a longer interval. Salicylic acid ointments and anhydrous preparations fall into the nonaqueous semisolid category and are assigned a beyond-use date of 180 days or the earliest expiration date of any component, whichever is shorter. Water-containing creams and gels containing salicylic acid are typically assigned a beyond-use date of 30 days at controlled room temperature because the aqueous phase supports microbial growth and physical instability. Salicylic acid lowers the pH of aqueous preparations, which can inhibit certain bacteria and fungi, but it is not a substitute for an appropriate preservative when the formulation contains water; USP <51> antimicrobial effectiveness testing should be considered for any aqueous multi-dose compounded preparation. Microbial examination by USP <61> and USP <62> may be used to verify that the total aerobic microbial count and specified pathogens meet the acceptance criteria for nonsterile topical products. The pH of the finished preparation is a release and stability parameter: when salicylic acid is formulated in a cream buffered to pH 5.0 or above, the free acid fraction decreases and the chemical stability of the salicylate salt may change, while acidification below pH 2.5 can produce excessive irritation and may compromise the physical stability of acid-sensitive emulsion systems. A pH range of 2.8–3.5 is generally maintained for hydroalcoholic salicylic acid gels intended for keratolysis, which corresponds to a non-ionized free acid fraction of approximately 23–60%; this range must be balanced against the degradation of acid-sensitive thickeners and the potential for corrosion of metal closure components.

Combining salicylic acid with urea at concentrations above 10% w/w produces a synergistic keratolytic effect on hyperkeratotic plaques, but the combination introduces a pH instability that is frequently underestimated in compounding practice. Urea hydrolyzes in aqueous media to ammonia and carbon dioxide, and the resulting rise in pH can convert salicylic acid into the poorly penetrating salicylate anion; this effect is accelerated above 40 °C and in the presence of moisture. A compounded cream containing 6% w/w salicylic acid and 20% w/w urea in a hydrophilic ointment base should be buffered to an initial pH of 3.0–4.0 using citric acid or lactic acid, and the preparation should be stored in a tightly closed, cool environment not exceeding 25 °C to slow urea hydrolysis. Without such control, the pH can drift upward by more than 2.0 pH units over a 30-day room-temperature storage period; published stability data for this specific combination are limited, but the mechanism of pH drift is well established. The same combination also increases the hygroscopicity of the preparation; in high-humidity environments above 60% RH, the cream may absorb water, soften, and lose its semisolid structure. In a compounding pharmacy, this behavior is observed as a decrease in viscosity and phase separation at the top of the jar, which is inconsistent with a reproducible dose when the patient applies a thin film.

When a compounded ointment exceeds 10% salicylic acid in combination with urea or lactic acid

When a compounded ointment exceeds 10% w/w salicylic acid and is combined with urea or lactic acid, the risk of excessive keratolysis and systemic absorption becomes clinically significant, particularly on denuded or fissured skin. Salicylic acid is absorbed through intact skin, and the absorbed fraction increases with increasing concentration, application area, occlusion, and disruption of the stratum corneum. Serum salicylate concentrations above 300 mg/L are associated with mild salicylism, including tinnitus, nausea, and tachypnea; severe toxicity can occur above 500 mg/L. Topical formulations of 20% w/w or higher applied to more than 20% body surface area, or to ulcerated skin, have been associated with systemic salicylate exposure in published case reports. The compounding pharmacist should limit the total application area, specify the amount to be applied per dose, and instruct the patient not to use occlusive dressings unless the prescriber has documented the need. Urea at 20% w/w or lactic acid at 10% w/w enhances penetration of salicylic acid by hydrating the stratum corneum and by disrupting barrier lipids; therefore the combination should be reserved for localized hyperkeratotic lesions rather than broad application. Although no globally harmonized dose limit exists for topical salicylic acid, institutional protocols often restrict application to 10 g/day of a 20% w/w preparation for intact plantar skin; beyond this, serum salicylate monitoring may be warranted in patients with renal impairment or low body mass.

Equipment selection for particle size reduction of salicylic acid in anhydrous bases follows standard dispersion technology for powdered actives with a low melting point and moderate aqueous solubility. Salicylic acid crystals are reduced by geometric dilution with a levigating agent such as mineral oil or propylene glycol, using a ratio of active to levigating agent of 1:1 to 1:2. The resulting paste is then passed through a three-roll ointment mill; roller gaps of 20–40 μm are used for topical ointments because larger particles above 75 μm produce grittiness and poor content uniformity. A production-scale three-roll mill with chromium-plated rollers and a throughput of 5–15 kg/h can reduce the mean volume diameter of salicylic acid to below 20 μm in two or three passes, and particle size distribution can be verified by laser diffraction as described in USP <429>. The use of high-shear rotor-stator homogenizers is reserved for creams and gels; when salicylic acid is added to a carbomer dispersion, a vortex should be formed at 1,500–3,000 rpm, and the dispersion should be deaerated under vacuum at −0.08 MPa to prevent the entrapment of air bubbles that accelerate oxidation. Salicylic acid is incompatible with ferric ion; contact with iron-containing equipment or contaminated water can produce a violet salicylate complex and should be avoided. Stainless steel of type 316L is preferred for manufacturing vessels, and edetate disodium at 0.05% w/w may be added to aqueous formulations only after confirming compatibility with the gel matrix.